Lewy Body
The latest sourced reporting on Lewy Body from Dementias Today: dated, and plain about what the evidence does and does not show.
A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.
A new scoping review pulls 108 studies on gardens, green space and outdoor programs into one picture. What it shows is real. What it leaves blank matters just as much.
Nine Italian memory clinics signed up to test whether a structured daily diary of behaviour beats standard care at lightening the load on families. Three years after the trial was registered, the results have not appeared.
A peer reviewed protocol lays out a 160 person randomized trial testing whether a mobile app, Brain CareNotes, that structures what family care partners report about behavioral symptoms of Alzheimer's and related dementias eases caregiver burden and those symptoms. The trial is still enrolling; no effectiveness results exist yet.
A small randomized trial of 36 caregiver-dyads in South Korea found that a mobile app translating caregiver-logged behavior into individualized, nonpharmacological activity suggestions was associated with lower overall behavioral and psychological symptoms, less agitation and depression, better nighttime sleep efficiency, and higher caregiver confidence, researchers reported.
At a cognitive neurology clinic, a voice AI ran the long history-taking interview while patients waited for their testing. A peer-reviewed SIGDIAL 2026 paper reports what it caught, and what it still cannot tell anyone.
A cluster-randomized trial in 38 primary care clinics is testing whether an alert built into the electronic health record can help clinicians catch cognitive impairment they might otherwise miss, with the first published results in on clinician confidence, not on diagnosis rates.
A pooled analysis of brain-scan data from 409 people finds that words alone and words paired with conditioning change pain-related brain activity in overlapping but partly different ways, a distinction researchers say matters for how future placebo-based protocols are designed and tested.
A February 2026 Nature review by Henrik Zetterberg and Barbara Bendlin gathers the scattered story of blood and spinal fluid tests across Alzheimer's and other neurodegenerative dementias, and shows plainly where the map runs out.
A UK feasibility study wore blinded Dexcom G7 sensors on 32 older inpatients with type 2 diabetes and cognitive impairment for up to 10 days, testing whether continuous glucose monitoring can be deployed on the ward at all, before any question of whether it changes outcomes.
A machine learning pipeline called ActiTect flagged isolated REM sleep behavior disorder using only wrist-worn actigraphy, not an overnight sleep lab study, in a multi-cohort analysis published in npj Digital Medicine.
The Swiss team behind an actigraphy tool for spotting REM sleep behavior disorder has trained deep learning models on the same wrist recordings to separate Parkinson's disease patients from controls, and to test whether the same digital signature shows up early in isolated RBD.
An audit of records at one large academic health system found that a diagnosis of dementia or cognitive impairment barely moves the odds a caregiver has been granted shared access to a patient's electronic health record portal, a gap researchers say undercuts every other tool built on top of it.
A long-term follow-up of the DREAMS START trial found that sleep improvements in people with dementia were still detectable 24 months after the program began, though the family caregivers' own sleep did not improve.
A new scoping review catalogs 43 studies of AI tools built for family caregivers of people with Alzheimer's disease and related dementias, from robots to chatbots. The authors found a wide range of functions on offer and called for rigorous, long-term testing that so far has not been done.
A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.
A 262-caregiver randomized trial of WeCareAdvisor, the web app that turns a caregiver's plain-language account of a behavior into a tailored, physician-shareable plan, found a modest but statistically significant drop in caregiver distress by three months. Two of its three prespecified primary measures, confidence and the behaviors themselves, showed no significant difference between groups.
A newly published study protocol describes a three year effort in South Korea to follow community dwelling seniors with mild cognitive impairment using wrist actigraphy, sweat patch sampling and indoor sensors, alongside yearly home visits, with the goal of building machine learning models of who progresses to dementia.
A memory clinic team at the University of Virginia drafted a short survey to gauge how ready a care partner feels to plan ahead. The instrument exists on paper. It has not yet been given to a single caregiver in a validation study.
Three months after opening the rewrite for public comment, HHS has formally issued its 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias, restructuring federal priorities around risk reduction, research, care and family support.
A lab study combining EEG, pupil tracking and behavioral testing found that when a sensory event matched what people expected, they judged its location faster, but recalled the exact spot less precisely, a pattern the researchers say reveals two separate brain processes, not one.
A nationwide study of more than 2,000 older insulin users with Alzheimer disease and related dementias found that those wearing a continuous glucose monitor had a 43 percent lower death rate and fewer hospital stays than those checking blood sugar with fingersticks, though several related safety measures did not reach statistical significance.
Governor Kathy Hochul has signed a law forcing New York's long-term care hotline, NY Connects, to actively point callers toward Alzheimer's and dementia programs rather than leaving them to ask. The catch: nothing changes for a full year.
In a 274-person trial spanning 43 countries, dementia caregivers who used a self-guided, chatbot-driven psychoeducation program called PDC30 reported less depression and less burden after one month than those left on a waiting list. No clinician ever entered the exchange.
A new legal analysis walks through every place in the world where voluntary assisted dying is lawful and finds that a dementia diagnosis, by itself, almost never clears the bar, even in the handful of countries that allow a person to request it in advance.
Across four hospitals and 70 clinics in Hawaii, an ambient AI scribe drafted more than 25,000 real visit notes in three months. It gave clinicians back time. Whether a caregiver's account arrives intact in the note is a question nobody has asked yet.
Twenty-two health and social care professionals across England describe, in a new qualitative study, how people with dementia who live alone with no family or friend nearby can vanish from the system's view at every stage, from the first missed sign to the day they go home from hospital with no one waiting.
A Lancet Psychiatry review maps the ways a clinician's wording shapes what a patient feels, and asks which of those ways survive telling the patient everything
The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.
A new discussion paper from the FDA's Digital Health Center of Excellence sketches a way to grade generative AI tools by risk, but it never says whether software that turns a caregiver's daily notes into a clinician's summary counts as a medical device at all. The public has until October 19 to weigh in.
A JAMA audit of every AI device the FDA has authorized for Alzheimer's disease and related dementias found the paperwork behind them seldom names the patients the software learned from. Race and ethnicity appeared for at most one device per source.
The Massachusetts House voted unanimously on July 29, 2026 to require acute care hospitals to notify a designated family member or caregiver soon after a dementia patient is admitted and again before discharge. The bill, which also expands diagnosis notification and creates a new MassHealth care coordination benefit, now heads to the Senate.
Governor Wes Moore has signed a law replacing Maryland's lone dementia director with a full state program, and ordered health officials to find out whether the state's clinicians are actually ready for the patients already walking into their offices.
Filed September 24 and still sitting in committee with Booker as its only sponsor, S.Res.910 points to an estimated 1.4 million Americans living with Lewy body dementia and asks for more research and better-trained clinicians. It carries no funding and no legal weight.
H.R.6130 would give Medicare, for the first time, legal authority to cover blood-based screening for Alzheimer's disease and related dementias. The bill sets January 1, 2028 as the earliest possible start date, a date that holds only if the measure becomes law.
A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.
UK Research and Innovation has launched the Dementia Challenge, funding real-world NHS trials of faster MRI scans, blood tests and remote cognitive assessments, with a target of diagnosing 92% of referred patients within 18 weeks, up from about 60% today.
Two Mount Sinai studies using engineered human brain tissue report that APOE4, the strongest genetic risk factor for Alzheimer's, drives a specific, experimentally reversible pattern of blood vessel scarring and protein buildup, distinct from the gene's broader population-level risk.
A bill introduced in the Senate would credit hours spent bathing, medicating and transporting a relative with an age-related condition toward eligibility for bigger retirement contributions, but it is still sitting in committee with no vote scheduled.
H.R. 3747 would add dementia care to the list of specialty topics eligible for federal Project ECHO training grants and reauthorize the program through 2031, but it has not become law.
The Credit for Caring Act, reintroduced in the House and Senate in March 2025, would create a new federal tax credit of up to $5,000 for working family caregivers. More than a year later, the bipartisan bill remains in committee with no vote scheduled.
A peer-reviewed report on the second Healthy Brain Initiative Summit for Public Health Action describes state and local officials from 43 jurisdictions converging on shared dementia priorities, while naming continued federal funding as essential to keeping the effort moving.
The Administration for Community Living has posted a new round of federal grants for state respite care systems, including a companion track set aside specifically for dementia-specific respite programs, agency notices show.
The National Institute on Aging has published the finalized report from its fourth triennial Dementia Care and Caregiving Research Summit, naming five research areas and a list of gaps it wants filled next, including a fresh estimate that dementia now costs the country up to $800 billion a year.
An analysis of brain tissue from 20 people who had dementia with Lewy bodies and 20 without found no link between how many Lewy bodies had formed and how many neurons or synapses were lost, unsettling a long-held assumption about what drives decline in the disease.
An op-ed in The Fulcrum argues aid-in-dying statutes are built for cancer timelines, not for capacity that goes first. It is an argument, not evidence, and the distinction matters.
Since July 1, 2026, residents of dedicated memory care units can no longer join the GUIDE Model, assisted living residents have lost access to its respite benefit, and providers must get CMS approval before signing new partnerships with residential care communities.
A national analysis of federal health survey data finds dementia caregivers report more intense caregiving than other caregivers nationally, but the size of that gap shifts sharply when researchers looked state by state.
A pooled analysis of 74 cohort studies found leisure-time exercise associated with lower dementia risk, while physical activity performed on the job was associated with higher risk, a split researchers say challenges blanket advice to "just be more active".
A 280-dyad trial in Norway measured, in hours per month, what family caregivers actually do, and found that a six-month coordinator program did not significantly ease the load.
A laboratory study in Communications Biology reports that disease-linked chemical changes expose a normally hidden sticky region of alpha-synuclein, letting it grab other proteins indiscriminately, a mechanism the authors call a 'Multifactorial Random Disorder Model.'
A synthesis of eight studies covering more than 3,000 people finds some respite models are linked to less caregiver stress and burden, but says the evidence on costs and quality is too weak to draw firm conclusions.
The OECD's new stocktake of national dementia policy catalogues strategies in 38 member countries and finds most of them have one. What it cannot find, in most cases, is the money and the monitoring that would turn the document into a service a family can actually reach.
The World Health Organization has released an executive summary distilling its second edition of dementia risk reduction guidelines for governments, replacing the reference document that has anchored national dementia plans since 2019.
In an 18-month trial of 2,176 families, two structured dementia care programs, one run through health systems and one through community organizations, did not ease caregiver strain or improve outcomes for people living with dementia compared with usual care. Caregivers did report greater satisfaction with the care itself.
The Lewy Body Dementia Association has funded a new multi-site study, called Clin-Syn, led by researchers at UT Health San Antonio and the University of Florida, to determine what positive or negative alpha-synuclein biomarker results should mean for diagnosis and care.
A full-year spending bill signed into law in February makes concrete a funding increase that had been advancing through Congress since mid-2025, splitting new money between two NIH institutes that lead the government's dementia research portfolio.
A new AARP valuation puts the replacement cost of unpaid family caregiving at just over $1 trillion for 2024, a figure the report says exceeds national Medicaid spending, though it does not separate out how much of that work involves caring for someone with dementia.
A Medicare claims study of insulin-treated older adults with Alzheimer's disease and related dementias found lower rates of death and hospitalization among those using continuous glucose monitors instead of fingerstick testing, though the specific glucose emergencies the devices are built to catch did not differ by a statistically significant margin.
A national study of 104,366 Medicare decedents with dementia links billed advance-care-planning visits to a cheaper, less hospital-centred final month. It is claims data, not a trial, and it cannot tell you what was said in the room.